Evidence map›Paper›PMID 40841956›Full record

ReviewJournal of translational medicine2025

m5C RNA modification in colorectal cancer: mechanisms and therapeutic targets.

Jiawei Wang, Cenyi Qi, Ran Wang, Yuepeng Cao, Yuping Zhou, Guoliang Ye

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Marked for Success: How RNA mCellular and molecular gastroenterology and hepatology · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiawei WangDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, 247 Renmin Road, Jiangbei District, Ningbo City, 315020, Zhejiang Province, China.
Cenyi QiDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, 247 Renmin Road, Jiangbei District, Ningbo City, 315020, Zhejiang Province, China.
Ran WangDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, 247 Renmin Road, Jiangbei District, Ningbo City, 315020, Zhejiang Province, China.
Yuepeng CaoDepartment of Colorectal and Anal Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, 315020, Zhejiang Province, China.
Yuping ZhouDepartment of Traditional Chinese Medicine, The First Affiliated Hospital of Ningbo University, 247 Renmin Road, Jiangbei District, Ningbo City, 315020, Zhejiang Province, China. fyzhouyuping@nbu.edu.cn.ORCID 0000-0001-8663-2153
Guoliang YeDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, 247 Renmin Road, Jiangbei District, Ningbo City, 315020, Zhejiang Province, China. yeguoliang@nbu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

5-Methylcytosine (m5C), an important RNA modification, has been extensively studied in colorectal cancer (CRC). In recent years, with advances in high-throughput sequencing technology and RNA modification detection tools, the role of m5C modification in tumorigenesis and development has been gradually elucidated and regulated by "writers," "erasers," and "readers," m5C modification affects many biological processes and cancer progression, including cell proliferation, autophagy, invasion, and apoptosis. In CRC, m5C modification affects cancer cell proliferation, migration, invasion, drug resistance, and immunotherapy resistance by regulating RNA stability, metabolic reprogramming, signalling pathway activation, and immune escape. Moreover, m5C modification provides potential biomarkers and targets for early diagnosis and efficacy prediction. In addition, studies on drugs that target m5C modification related proteins have shown that intervention in m5C modification may provide new directions for immunotherapy and molecular therapy for patients with CRC. In summary, m5C modification, an important epigenetic regulators in CRC, provides a new perspective on the mechanism underlying cancer therapy and precision medicine research. Future research should focus on revealing the specific role of m5C modification in the tumor microenvironment and drug resistance mechanisms and promote its clinical translation in diagnosis and treatment.

Indexed as

5-MethylcytosineColorectal NeoplasmsMolecular Targeted TherapyRNA Processing, Post-TranscriptionalAnimalsHumans5-MethylcytosineColorectal cancerDNMT2Early diagnosisNSUN2RNA 5-methylcytosine (m5C)Targeted therapy

Identifiers

PMID40841956
PMCPMC12372324

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.